About the Journal

Precision Cancer Medicine

Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216) is an open access, peer-reviewed online journal dedicated to precise diagnosis and treatment of cancers and personalized care for patients. With an aim of better understanding and management of cancers, the journal focuses on precision cancer researches on different kinds of cancers and different aspects of cancer research, encompassing advanced basic researches, translational researches and up-to-date clinical practice in the field of precision medicine and engaging multidisciplinary teams of oncology, pathology, imaging, radiotherapy, chemotherapy, surgery, anesthesiology, nursing, etc. It is to improve the health care from all aspects of prevention, diagnosis, treatment and recovery management of cancer care for the patients. PCM welcomes submissions of Original Articles, Review Articles, Editorials, Editorial Commentaries, Case Reports, Clinical Guidelines, etc.

Precision Cancer Medicine is the official journal of Fudan University Shanghai Cancer Center.

Submission Turnaround Time:
External peer review: 1-2 months.
Acceptance to Publication Ahead of Print: 20 days.
Acceptance to Publication: 1-3 months. Original Articles are listed as priority.

Introduction of Fudan University Shanghai Cancer Center

Fudan University Shanghai Cancer Center (FUSCC, http://www.shca.org.cn/english), is engaged in clinical practice, medical education, oncological research and cancer prevention in China. Historically, it can be traced back to Sino-Belgian Radium Institute established on March 1, 1931, the earliest specialized hospital of oncology in China.

FUSCC topped the counterparts across the China in terms of medical operation efficiency. The year of 2017 witnessed 1,339,000 outpatient and emergency visits, including 160,000+ first visits; 37,284 surgeries and 76,381 hospitalizations. As to scientific research, they published 338 SCI papers in journals such as JCO, Nature, JNCI, etc.

FUSCC, while deeply committing to the basic mission to care for the patient, is dedicated to building national and international collaborative partnerships and cherishing its influential image.

Internationally, FUSCC signed the sister-institution agreement, respectively, with MD Anderson Cancer Center at Texas in USA; National University Cancer Institute Singapore; Institut Gustave Roussy in France; Cancer Research Institute of Kanazawa University, Japan; European Institute of Oncology, Italy; DUKE Cancer Institute, USA; Peter MacCallum Cancer Centre, Australia; and The Princess Margaret Cancer Centre, Canada for the purpose of promoting bilateral collaborations and exchanges in therapy, research, training and referral. So far, FUSCC has established eight sister-institution/hospital partnerships, advancing the construction of its own disciplines and improving its academic prestige in the world.

Publisher

AME Publishing Company:
Address: Rm C, 16/F, Kings Wing Plaza 1, No. 3 On Kwan Street, Shatin, NT, Hong Kong
Phone: +86 20 66355775
Email: pcm@amegroups.com